Human immunodeficiency virus type 1 (HIV-1), like all retroviruses, depends upon the integration of a DNA copy of its viral genome into host cell chromosomes as part of its infection cycle. The HIV-1 integrase (IN) enzyme mediates this insertion of viral DNA into the human genome and it is one of three virally-encoded enzymes required for virus replication. Because the proviral integration event is essential for HIV-1 replication, the HIV-1 IN enzyme remains a promising target for antiviral drug development to treat patients with AIDS.

This purified HIV-1 Integrase prepartion is enzymatically active in DNA strand-transfer assays and (due to the N155H mutation) is >10-fold resistant to the inhibitor Elvitegravir.

SOURCE:                                 

HIV-1 Integrase is an affinity-purified enzyme that catalyzes the insertion of proviral DNA sequences into target DNA. This enzyme contains the amino acid substitutions F185H. Like the F185K mutation (J Biol Chem 271:7712, 1996), the F185H mutation makes the enzyme more soluble without affecting in vitro activity. Additionally, the N155H mutation has been reported to confer >10-fold resistance to Elvitegravir and partial resistance to Raltegravir..

RECONSTITUTION:             

Reconstitute lyophilized HIV-1 Integrase in 100 µL deionized H₂O for 100 µg quantity. The enzyme is stable to freeze-thawing.

CONCENTRATION:              

1 mg/mL in deionized H₂O after reconstitution.

PURITY & STERILITY:          

HIV-1 Integrase has been shown to be >90% pure by SDS-PAGE. NOTE: THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN CLINICAL OR DIAGNOSTIC PROCEDURES.

STORAGE & HANDLING:  

Store lyophilized sample at -20ºC or -70ºC prior to reconstitution. Once the integrase enzyme has been reconstituted, store at -70ºC.